Unknown PHASE2 INTERVENTIONAL 2-arm NCT04801342

Neurocognitive Outcome of Bilateral or Unilateral Hippocampal Avoidance WBRT With Memantine for Brain Metastases

Neurocognitive Outcome of Conformal Whole Brain Radiotherapy With Bilateral or Unilateral Hippocampal Avoidance Plus Memantine for Brain Metastases: A Phase II Single Blind Randomized Trial

Sponsor: National Taiwan University Hospital

Conditions Metastatic Malignant Neoplasm to Brain

Interventions Conformal Whole Brain Radiotherapy with Bilateral Hippocampal Avoidance Conformal Whole Brain Radiotherapy with Unilateral Hippocampal Avoidance Memantine Hydrochloride

Updated 4 times since 2021 Last updated: Mar 14, 2021 Started: Apr 1, 2021 Primary completion: Jan 1, 2024 Completion: Feb 28, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Malignant Neoplasm to Brain, this trial is ongoing. The trial is conducted by National Taiwan University Hospital and has accumulated 4 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Apr 2025 — Present [monthly]

Unknown PHASE2

Status: Recruiting → Unknown
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Apr 2021 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Taiwan University Hospital

Data source: National Taiwan University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Taipei, Taiwan